Journal article
Managing the risk of circulating vaccine-derived poliovirus during the endgame: oral poliovirus vaccine needs
The Global Polio Eradication Initiative plans for coordinated cessation of oral poliovirus vaccine (OPV) use, beginning with serotype 2-containing OPV (i.e., OPV2 cessation) followed by the remaining two OPV serotypes (i.e., OPV13 cessation). The risk of circulating vaccine-derived poliovirus (cVDPV) outbreaks after OPV cessation of any serotype depends on the serotype-specific population immunity to transmission prior to its cessation. Based on an existing integrated global model of poliovirus risk management policies, the researchers estimate the serotype-specific OPV doses required to manage population immunity for a strategy of intensive supplemental immunization activities (SIAs) shortly before OPV cessation of each serotype. The strategy seeks to prevent any cVDPV outbreaks after OPV cessation, although actual events remain stochastic.
Authors
Languages
- English
Publication year
2015
Journal
BMC Infectious Diseases
Volume
15
Type
Journal article
Categories
- Service delivery
Diseases
- Polio
Tags
- OPV